Enanta Pharma (ENTA) Misses Q3 EPS by 1c

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of $0.97, $0.01 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.93 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04